Back to Search Start Over

Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression

Authors :
Philip B. Mitchell
Eduard Vieta
Robert W. Baker
Karin Beymer
Charles L. Bowden
Gary S. Sachs
Terence A. Ketter
Gary D. Tollefson
Angela R. Evans
Sanjay Dubé
Mauricio Tohen
Alan Breier
R.C. Risser
Franca Centorrino
Joseph R. Calabrese
Source :
Archives of General Psychiatry. 60:1079
Publication Year :
2003
Publisher :
American Medical Association (AMA), 2003.

Abstract

Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression.To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.Double-blind, 8-week, randomized controlled trial.Eighty-four sites (inpatient and outpatient) in 13 countries. Patients A total of 833 randomized adults with bipolar I depression with a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 20. Intervention Patients were randomly assigned to receive placebo (n = 377); olanzapine, 5 to 20 mg/d (n = 370); or olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d (n = 86).Changes in MADRS total scores using mixed-effects model repeated-measures analyses.During all 8 study weeks, the olanzapine and olanzapine-fluoxetine groups showed statistically significant improvement in depressive symptoms vs the placebo group (P.001 for all). The olanzapine-fluoxetine group also showed statistically greater improvement than the olanzapine group at weeks 4 through 8. At week 8, MADRS total scores were lower than at baseline by 11.9, 15.0, and 18.5 points in the placebo, olanzapine, and olanzapine-fluoxetine groups, respectively. Remission criteria were met by 24.5% (87/355) of the placebo group, 32.8% (115/351) of the olanzapine group, and 48.8% (40/82) of the olanzapine-fluoxetine group. Treatment-emergent mania (Young Mania Rating Scale score15 at baseline andor =15 subsequently) did not differ among groups (placebo, 6.7% [23/345]; olanzapine, 5.7% [19/335]; and olanzapine-fluoxetine, 6.4% [5/78]). Adverse events for olanzapine-fluoxetine therapy were similar to those for olanzapine therapy but also included higher rates of nausea and diarrhea.Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine is more effective than olanzapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms.

Details

ISSN :
0003990X
Volume :
60
Database :
OpenAIRE
Journal :
Archives of General Psychiatry
Accession number :
edsair.doi.dedup.....af8b80ef045758fa476c4ab0bd29b08c
Full Text :
https://doi.org/10.1001/archpsyc.60.11.1079